An Antioxidant Drug For The Treatment Of Pd Using Nanoemulsion

Abstract

Dopaminergic (DAergic) neurons of the Substantia Nigra are selectively killed in Parkinson's disease (PD), a degenerative neurological illness. Yet without a cure, PD is an illness whose pathophysiology is poorly understood. The primary focus of today's pharmaceutical therapies is the alleviation of symptoms to enhance quality of life. As a result, the search for new PD treatments that can not only improve symptoms is urgent, but also arrest or reverse the neuronal damage that has been shown to impede the disease's development. An approach based on spontaneous emulsification was used to create the nanoemulsion, which was then homogenized under high pressure. Nigral degeneration is accelerated by oxidative stress in both sporadic and familial PD. We begin by taking a look at how much is now understood about how oxidative stress, mitochondrial dysfunction, and PD are all linked. The results of administering drugs that reduce oxidative stress or alleviate mitochondrial dysfunction to animal models or PD patients are then examined.